Curated News
By: NewsRamp Editorial Staff
May 13, 2026

Lantern Pharma Raises $4.4M, Spins Out AI Platform withZeta.ai

Discuss on Substack View History of this news story on GitHub
Original Source

TLDR

  • Lantern Pharma's $4.4M direct offering and AI platform spin-off can boost shareholder value and market position.
  • Lantern Pharma uses its RADR AI platform to analyze cancer data, developing drugs like LP-184 for targeted therapies.
  • Lantern Pharma's AI-driven approach aims to create more effective cancer treatments, improving patient outcomes.
  • Lantern Pharma's withZeta.ai AI co-scientist platform is now available as a subscription service for drug research.

Impact - Why it Matters

This news matters because Lantern Pharma is not only advancing its clinical pipeline of cancer therapies but also creating a new revenue stream by spinning out its AI platform withZeta.ai as an independent entity. This move could accelerate the adoption of AI in drug discovery and development, potentially leading to more efficient and targeted cancer treatments. For investors, the offering provides capital to support ongoing trials and expansion, while the commercialization of withZeta.ai opens up a new market for AI-driven biomedical research tools. The success of this strategy could position Lantern as a key player in the convergence of AI and precision oncology.

Summary

Lantern Pharma (NASDAQ: LTRN), a clinical-stage AI-driven precision oncology company, has announced a definitive agreement to raise approximately $4.4 million through a registered direct offering. The offering involves the sale of 2,135,923 shares of common stock (or pre-funded warrants) at $2.06 per share, along with a concurrent private placement of unregistered warrants. Lantern plans to use the proceeds to support its pipeline and to create an independent business entity composed of its AI platform, withZeta.ai, and related technologies and personnel.

Lantern Pharma’s core mission is to leverage AI and machine learning, particularly its proprietary RADR platform, to transform cancer therapy development. Its clinical pipeline includes LP-184 (acylfulvene), LP-284 (a TC-NER targeting compound), and LP-300 (cisplatin/ethacraplatin analog), which is being evaluated in the HARMONIC Phase 2 trial for never-smoker lung adenocarcinoma patients. LP-184 is also being developed for pediatric CNS cancers through Starlight Therapeutics, a wholly owned CNS-focused subsidiary. Notably, withZeta.ai, Lantern’s multi-agentic AI co-scientist platform, is now commercially available as a subscription-based research platform for the global biomedical community, representing a new revenue stream. The company operates an AI Center of Excellence in Bengaluru, India, and is headquartered in Dallas, Texas.

The news was disseminated by BioMedWire (BMW), a specialized communications platform focusing on Biotech, Biomedical, and Life Sciences sectors. BMW is part of the Dynamic Brand Portfolio @ IBN, which offers services including press release distribution via InvestorWire, editorial syndication to 5,000+ outlets, and social media distribution. This announcement underscores Lantern Pharma’s strategic moves to advance its AI-driven precision oncology pipeline and commercialize its AI platform for broader biomedical research applications.

Source Statement

This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Lantern Pharma Raises $4.4M, Spins Out AI Platform withZeta.ai

blockchain registration record for this content.